Skip to main content
Veterinary Medicines

Bovilis Ringvac vet. Pulver och vätska till injektionsvätska, suspension

Authorised
  • Trichophyton verrucosum, strain LTF-130, Live
  • Water

Product identification

Medicine name:
Bovilis Ringvac vet. Pulver och vätska till injektionsvätska, suspension
Active substance:
  • Trichophyton verrucosum, strain LTF-130, Live
  • Water
Target species:
  • Cattle
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Trichophyton verrucosum, strain LTF-130, Live
    7.32
    log10 colony forming unit(s)
    /
    1.00
    Dose
  • Water
    2.00
    millilitre(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Powder and solvent for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Milk
        0
        day
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AP01
Authorisation status:
  • Valid
Authorised in:
  • Sweden
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Benchmark Vaccines Limited
  • Intervet International B.V.
Responsible authority:
  • Swedish Medical Products Agency
Authorisation number:
  • 10725
Date of authorisation status change:

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 26/04/2022

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 26/04/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."